Dr. Nagareddy’s research mainly focuses on understanding the pathological basis of the so-called “cardiovascular risk factors” in diabetes, obesity, rheumatoid arthritis etc. The lab is interested in examining the role of neutrophil-derived proteins, S100A8 and S100A9 that are emerging as key signaling molecules in chronic-low grade inflammation. His laboratory is also interested in developing various therapeutic strategies (e.g. monoclonal antibodies, pharmacological inhibitors) to reduce inflammation and improve outcomes in cardiovascular (e.g. atherosclerosis, heart failure) and metabolic diseases (e.g. diabetes, obesity, insulin resistance) by targeting signaling pathways of neutrophils.


  • PhD: University of British Columbia, Canada, Pharmacology
  • Postdoctoral training: Columbia University, NY and University of Kentucky, KY

Research Interests

  • Ischemic heart disease, diabetes, obesity
  • Myocardial repair/regeneration
  • DAMPs, Inflammasome signaling
  • Neutrophils, Platelets
  • Myelopoiesis, Thrombopoiesis

Current Funding

  • R00 HL122505
    Title: Mechanisms of Monocytosis in Obesity: Role: PI 

  • R01 HL137799
    Title: Thrombopoiesis in Diabetes: Role of Damage Associated Molecular Patterns

PubMed articles